Who Attends
The following represents a selection of companies who have attended or are confirmed to attend upcoming editions. In line with data protection regulations, we do not disclose individual delegate information. You can explore a range of C-suite testimonials through the link below or contact us for further details.
Who Attends
Qualifies Invitation
Invitation-Only: DDIF 2026 Audience Preview
NORTHERN EUROPE
Focus: AI-driven discovery, translational medicine, data infrastructure and precision design.
AstraZeneca (UK / Sweden)
GSK (UK)
Novo Nordisk (Denmark)
Lundbeck (Denmark)
Genmab (Denmark / Netherlands)
Exscientia (UK)
BenevolentAI (UK)
Aqemia (France — AI drug discovery)
Oxford Biomedica (UK)
Immunocore (UK)
Adaptimmune (UK)
Orchard Therapeutics (UK)
ReNeuron (UK)
eTheRNA Immunotherapies (Belgium)
uniQure (Netherlands)
Galapagos NV (Belgium / Netherlands)
BioNTech SE (Germany)
Evotec SE (Germany)
Welcomed Invites
Chief Scientific Officer, VP AI & Data Science, Head of Computational Discovery, VP Translational Medicine, Head of Target Discovery, Chief Data Officer, Director Discovery Platforms, VP Preclinical Strategy.
Welcomed Invites
Head of Discovery Innovation, VP AI Drug Design, Chief Translational Officer, Global Head Digital Discovery, VP Data Sciences, Director External Innovation, Head of Partnerships Europe.
Genentech (USA)
Recursion Pharmaceuticals (USA - AI discovery)
Insilico Medicine (USA / Hong Kong)
Relay Therapeutics (USA)
Tempus AI (USA)
Arzeda (USA - computational protein design)
Welcomed Invites
Chief Scientific Officer, VP AI Drug Discovery, Head of Data Science, VP Platform Biology, Director Computational Chemistry, Head of Digital R&D, VP Translational Platforms.
SOUTHERN EUROPE / GLOBAL SOUTH
Focus: translational innovation, AI adoption in discovery, data ethics and clinical validation pathways.
Chiesi Farmaceutici (Italy)
Grifols (Spain)
PharmaMar (Spain)
MedinCell (France)
Anemocyte (Italy)
CART Therapy Center (Spain)
Lonza Group (Switzerland)
WuXi AppTec / WuXi Biologics (China HQ / EU ops)
Minaris Regenerative Medicine (Japan / EU base in Munich)
Fujifilm Diosynth Biotechnologies (Japan / UK / Denmark ops)
Takeda Pharmaceuticals (Japan HQ / Europe hub in Zurich)
Astellas Pharma (Japan)
Kyorin Pharma (Japan)
Samsung Biologics (South Korea)
KBI Biopharma (US HQ / Geneva EU hub)
Tigen Pharma (Switzerland)
Welcomed Invites
VP Discovery Strategy, Global Head AI Integration, Director Translational Science, VP Digital R&D, Head of Data Platforms, VP Partnerships, Director Innovation Strategy.
DAX / CENTRAL EUROPE / MULTINATIONALS
Focus: global discovery networks, AI platforms and data-enabled translational science.
Roche (Switzerland)
Novartis (Switzerland)
Bayer AG (Germany)
Merck KGaA (Germany)
Sanofi (France)
Boehringer Ingelheim (Germany)
CureVac (Germany)
MorphoSys AG (Germany)
BioM Biotech Cluster Development (Germany)
CeGaT GmbH (Germany)
Replimune (UK / Germany ops)
Polpharma Biologics (Poland)
Miltenyi Biotec (Germany)
ASIA / REST OF WORLD
Focus: AI-enabled discovery ecosystems, data-driven collaboration and cross-border translational partnerships.
Takeda Pharmaceuticals (Japan)
Astellas Pharma (Japan)
Daiichi Sankyo (Japan)
Ono Pharmaceutical (Japan)
Eisai Co. (Japan)
Samsung Biologics (South Korea)
SK Biopharmaceuticals (South Korea)
WuXi AppTec (China)
WuXi Biologics (China)
Insilico Medicine (Hong Kong / Singapore)
BioMap (China)
BeiGene (China)
Zai Lab (China)
Bharat Biotech (India)
Biocon (India)
CSL Limited (Australia)
Welcomed Invites
Chief Scientific Officer, VP AI & Automation, Head of Translational Research, Global Head Digital Strategy, Director Computational Biology, VP Innovation Partnerships, Head of AI R&D.
NORTH AMERICA
Focus: computational chemistry, AI-first R&D platforms, automation and next-generation target discovery.
Merck & Co. (USA)
Pfizer (USA)
Moderna Therapeutics (USA)
Amgen (USA)
Gilead Sciences (USA)
Regeneron Pharmaceuticals (USA)
Vertex Pharmaceuticals (USA)
Eli Lilly (USA)
Johnson & Johnson (USA)
Uwe Gottschalk
Operating Partner at Keensight Capital (Former CSO Lonza)
"It's not an event - it's a tradition."